327 related articles for article (PubMed ID: 21799304)
1. Antagonistic control of muscle cell size by AMPK and mTORC1.
Mounier R; Lantier L; Leclerc J; Sotiropoulos A; Foretz M; Viollet B
Cell Cycle; 2011 Aug; 10(16):2640-6. PubMed ID: 21799304
[TBL] [Abstract][Full Text] [Related]
2. Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK.
White JP; Puppa MJ; Gao S; Sato S; Welle SL; Carson JA
Am J Physiol Endocrinol Metab; 2013 May; 304(10):E1042-52. PubMed ID: 23531613
[TBL] [Abstract][Full Text] [Related]
3. Coordinated maintenance of muscle cell size control by AMP-activated protein kinase.
Lantier L; Mounier R; Leclerc J; Pende M; Foretz M; Viollet B
FASEB J; 2010 Sep; 24(9):3555-61. PubMed ID: 20460585
[TBL] [Abstract][Full Text] [Related]
4. Targeting deregulated AMPK/mTORC1 pathways improves muscle function in myotonic dystrophy type I.
Brockhoff M; Rion N; Chojnowska K; Wiktorowicz T; Eickhorst C; Erne B; Frank S; Angelini C; Furling D; Rüegg MA; Sinnreich M; Castets P
J Clin Invest; 2017 Feb; 127(2):549-563. PubMed ID: 28067669
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-451 regulates AMPK/mTORC1 signaling and fascin1 expression in HT-29 colorectal cancer.
Chen MB; Wei MX; Han JY; Wu XY; Li C; Wang J; Shen W; Lu PH
Cell Signal; 2014 Jan; 26(1):102-9. PubMed ID: 23899558
[TBL] [Abstract][Full Text] [Related]
6. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth.
Shaw RJ
Acta Physiol (Oxf); 2009 May; 196(1):65-80. PubMed ID: 19245654
[TBL] [Abstract][Full Text] [Related]
7. Role of AMP-activated protein kinase activators in antiproliferative multi-drug pituitary tumour therapies: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumour cells.
Tulipano G; Faggi L; Cacciamali A; Spinello M; Cocchi D; Giustina A
J Neuroendocrinol; 2015 Jan; 27(1):20-32. PubMed ID: 25323047
[TBL] [Abstract][Full Text] [Related]
8. Mechanical stretch activates mammalian target of rapamycin and AMP-activated protein kinase pathways in skeletal muscle cells.
Nakai N; Kawano F; Nakata K
Mol Cell Biochem; 2015 Aug; 406(1-2):285-92. PubMed ID: 25971373
[TBL] [Abstract][Full Text] [Related]
9. AMP-activated Protein Kinase (AMPK) Control of mTORC1 Is p53- and TSC2-independent in Pemetrexed-treated Carcinoma Cells.
Agarwal S; Bell CM; Rothbart SB; Moran RG
J Biol Chem; 2015 Nov; 290(46):27473-86. PubMed ID: 26391395
[TBL] [Abstract][Full Text] [Related]
10. Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas.
Rothbart SB; Racanelli AC; Moran RG
Cancer Res; 2010 Dec; 70(24):10299-309. PubMed ID: 21159649
[TBL] [Abstract][Full Text] [Related]
11. Endothelial AMPK activation induces mitochondrial biogenesis and stress adaptation via eNOS-dependent mTORC1 signaling.
Li C; Reif MM; Craige SM; Kant S; Keaney JF
Nitric Oxide; 2016 May; 55-56():45-53. PubMed ID: 26989010
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of cardiomyogenesis of embryonic stem cells by nitric oxide downstream of AMP-activated protein kinase and mTOR signaling pathways.
Padmasekar M; Sharifpanah F; Finkensieper A; Wartenberg M; Sauer H
Stem Cells Dev; 2011 Dec; 20(12):2163-75. PubMed ID: 21470048
[TBL] [Abstract][Full Text] [Related]
13. Activation of AMP-activated protein kinase is involved in vincristine-induced cell apoptosis in B16 melanoma cell.
Chen MB; Shen WX; Yang Y; Wu XY; Gu JH; Lu PH
J Cell Physiol; 2011 Jul; 226(7):1915-25. PubMed ID: 21506122
[TBL] [Abstract][Full Text] [Related]
14. Proliferating effect of orotic acid through mTORC1 activation mediated by negative regulation of AMPK in SK-Hep1 hepatocellular carcinoma cells.
Jung EJ; Lee KY; Lee BH
J Toxicol Sci; 2012; 37(4):813-21. PubMed ID: 22863860
[TBL] [Abstract][Full Text] [Related]
15. Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK.
Zhou H; Shang C; Wang M; Shen T; Kong L; Yu C; Ye Z; Luo Y; Liu L; Li Y; Huang S
Biochem Pharmacol; 2016 Sep; 116():39-50. PubMed ID: 27396756
[TBL] [Abstract][Full Text] [Related]
16. The lipid peroxidation product 4-hydroxy-trans-2-nonenal causes protein synthesis in cardiac myocytes via activated mTORC1-p70S6K-RPS6 signaling.
Calamaras TD; Lee C; Lan F; Ido Y; Siwik DA; Colucci WS
Free Radic Biol Med; 2015 May; 82():137-46. PubMed ID: 25617592
[TBL] [Abstract][Full Text] [Related]
17. A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway.
Kimura N; Tokunaga C; Dalal S; Richardson C; Yoshino K; Hara K; Kemp BE; Witters LA; Mimura O; Yonezawa K
Genes Cells; 2003 Jan; 8(1):65-79. PubMed ID: 12558800
[TBL] [Abstract][Full Text] [Related]
18. Molecular brakes regulating mTORC1 activation in skeletal muscle following synergist ablation.
Hamilton DL; Philp A; MacKenzie MG; Patton A; Towler MC; Gallagher IJ; Bodine SC; Baar K
Am J Physiol Endocrinol Metab; 2014 Aug; 307(4):E365-73. PubMed ID: 24961241
[TBL] [Abstract][Full Text] [Related]
19. AMP-activated protein kinase enhances the expression of muscle-specific ubiquitin ligases despite its activation of IGF-1/Akt signaling in C2C12 myotubes.
Tong JF; Yan X; Zhu MJ; Du M
J Cell Biochem; 2009 Oct; 108(2):458-68. PubMed ID: 19639604
[TBL] [Abstract][Full Text] [Related]
20. AMPK activation attenuates S6K1, 4E-BP1, and eEF2 signaling responses to high-frequency electrically stimulated skeletal muscle contractions.
Thomson DM; Fick CA; Gordon SE
J Appl Physiol (1985); 2008 Mar; 104(3):625-32. PubMed ID: 18187610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
